Clinical Trial

A Phase I Study of CS5007 in Participants With Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a first-in-human (FIH), open-label, and multi-center Phase I study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of CS5007 as monotherapy in participants with advanced solid tumors. The study is comprised of a Phase Ia dose escalation and Phase Ib dose expansion.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-08-15
notable Trial sites expanded: 3 -> 7 locations 2026-06-19
Trial Details
NCT Number NCT07622524
Lead Sponsor CStone Pharmaceuticals
Conditions Advanced Solid Tumors
Enrollment 310 participants
Start Date 2026-07-16
Primary Completion 2028-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-14